Jun Bao – President & CEO, Impact Therapeutics, China
Dr Jun Bao, appointed president and CEO of Impact Therapeutics in October 2018, shares his aspirations for Impact to be a leader in synthetic lethality in oncology; the importance of…
Funded by venture capital and based in China, IMPACT Therapeutics, Inc. (IMPACT) is dedicated to the discovery, development and commercialization of novel and “best-in-class” therapeutics to treat cancer and other life-threatening diseases. IMPACT is a clinical-stage company with a unique small-molecule drug discovery and development platform targeting DDR. IMPACT’s leading program, PARP inhibitor IMP4297, is currently in clinical development.
Contact
Room 603, Building 3, 111 Xiangke Road, Pudong District, Shanghai 200135, China
Tel: +86 21 68411121
Website: http://impacttherapeutics.com
Dr Jun Bao, appointed president and CEO of Impact Therapeutics in October 2018, shares his aspirations for Impact to be a leader in synthetic lethality in oncology; the importance of…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Merck’s $2.13B deal with SciBrunch for KRAS G12D inhibitor SPR2015, Abogen’s $7.78B partnership with Novartis for an mRNA T-cell…
The global AI-in-clinical-trials market is forecast to grow at a 22.6 percent CAGR through 2030, reaching roughly USD 6.5 billion, as sponsors push CROs to demonstrate concrete efficiency gains rather…
China has rapidly become the world’s leading country for clinical trial volume, alongside the stratospheric growth of its local biotech industry, which now accounts for almost a third of the…
Chinese biotechs are now outpacing multinationals at getting drugs into pivotal trials — but MNCs still win the race to final approval. In this piece from the September 2026 edition…
Excalipoint is betting that the next chapter of T-cell engagers will be written in solid tumours, where the modality is beginning to challenge the boundaries of cancer immunotherapy. Co-Founder, Chairman…
CirCode Biomed is emerging at the forefront of a small but fast-evolving field seeking to turn circular RNA into a new class of medicines. From its roots in pioneering academic…
Chinese pharmaceutical companies are increasingly seeking drug approval in the EU, US, and Australia, beyond the NMPA. Daphne Smyth of Veristat has witnessed this shift firsthand, advising sponsors on data…
Five conferences, anxiety spreading across five continents, one unmistakable pattern: the global pharmaceutical industry is transforming at a dizzying pace. From Philadelphia to Geneva, from Istanbul to Chicago and London,…
For two decades the case for running a clinical trial in Asia was essentially arithmetic: the same study, for less money. That argument has not gone away, but it is…
Our goal is to generate rigorous clinical data demonstrating that these therapies can deliver meaningful and lasting benefits for patients For decades, neurological diseases such as Parkinson’s disease, spinal cord…
China has built one of the world’s most advanced digital health ecosystems — large, fast-moving, and integrated across hospitals, internet platforms, insurers, pharmaceutical companies, and regulators. AI is now embedded…
As the global clinical development landscape becomes more fragmented and competitive, biotechs increasingly need partners that can help them navigate regulatory complexity, identify the right trial locations, and generate meaningful…
See our Cookie Privacy Policy Here
